Download presentation
Presentation is loading. Please wait.
Published byNatalie Thornton Modified over 6 years ago
3
CoreValve US Pivotal Trial High-Risk Arm
4
Device and Access Routes
5
End Points
6
Patient Eligibilitya
7
Study Disposition
8
Baseline Demographics
9
Results 1 Year All-Cause Mortality
10
Results Noninferiority and Superiority
11
Results 2-Year All-cause Mortality (Preliminary Results)
12
Clinical Patient Outcomes
13
Results All Stroke
14
Secondary End Points
15
1-Year MACCE
16
Other End Points
17
Paravalvular Regurgitation
18
Subgroup Analysis 1 Year
19
Subgroup Analysis 1 Year (cont)
20
Conclusion
21
CoreValve US Pivotal Trial In Context
22
What Did We Learn?
23
Surgical Outcomes
24
Patient Selection What Is High Risk?
25
Key Inclusion Criteria
26
Study Population – In Context
27
Expanded Patient Population
28
Loss to Follow-Up: Sensitivity Analyses
29
Future TAVR vs SAVR Trial Design Considerations
30
TAVR in Community Practice
31
The TVT Registry
32
TVT 1-Year Outcomesa
33
TAVR Device Comparison Trials
34
CHOICE Key Outcomes
35
CHOICE Clinical Implications
36
TAVR in Clinical Practice: Moving Forward
37
Abbreviations
38
Abbreviations (cont)
39
References
40
References (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.